Betagenon/Baltic Bio announces positive results from a 28 day Phase IIa trial of the first-in-class AMPK activator O304 in Type 2 Diabetics
O304 reduces significantly fasting plasma glucose (FPG) in type 2 diabeticsThe main study results are not yet finalized. Review of the initial data showed that a number of patients who were included based on HbA1c at screening, had FPG below 7 mM or above 13.3 mM at day 1, and that the data analysis of FPG required a post hoc analysis plan.In type 2 diabetic patients on Metformin with FPG >7 mM and < 13.3 mM ( >126 and < 240 mg/dl) at day 1, where FPG >13.3mM defines uncontrolled hyperglycemia, there were statistical significant differences between the treatment groups in the absolute
Thin, flexible, environmentally sealed component enhances performance of Movesense motion measurementOULU, FINLAND/HELSINKI, FINLAND (2 November 2017) – Today, Suunto announced that TactoTek has been awarded the mass production contract for the Suunto Movesense Smart connector, an Injection Molded Structural Electronics (IMSE) solution that is part of the Suunto Movesense platform (www.movesense.com). TactoTek will manufacture the Smart connector in its Oulu, Finland factory.
Movesense can track anything that moves: it is a physical toolkit and open development environment for motion
